Abstract:Breast cancer (BC) is the most frequently diagnosed cancer in women worldwide with more than 2 million new cases in 2020. The efficacy of immunotherapies for BC is limited, with response rates of <10% for anti-PD-1/PDL1 monotherapy in pre-treated triple-negative breast cancer (TNBC) patients and even lower in subtypes that express human epidermal growth factor receptor 2 (HER2+) and/or hormone receptors. Hence, there is an urgent need to improve immune based strategies for BC. One possible approach to enhance response is the application of intratumoral (IT) immunotherapy utilizing IL-12; a potent pro-inflammatory cytokine that is critical in producing an anti-tumor response. However, systemic delivery of IL-12 has substantial toxicity and localized delivery of protein has insufficient residence time. To circumvent these issues, we have previously reported the efficacy of intratumorally injected plasmid IL-12 (pIL-12-EP) followed by electroporation in a TNBC mouse model and in clinical trials. Following pIL-12-EP, treated tumor expressed genes that were associated with increased CD8+ T cell infiltration, activation, trafficking, antigen presentation, and exhaustion. Single-cell RNA sequencing (scRNAseq) of tumor infiltrating immune cells from treated tumors revealed a striking enrichment of the CXCL9/10/11/CXCR3 family. This CXCR3 axis is upregulated in response to IFNγ production and has been studied extensively in melanoma and NSCLC patients as a potential predictive biomarker for responses to immune checkpoint inhibitors but has not been well characterized in BC. We hypothesized that this axis may be the critical component downstream of pIL-12-EP treatment that is responsible for anti-tumor responses and that targeting it will be effective in other molecular subtypes of BC beyond TNBC. We first evaluated the expression of CXCR3 by tumor infiltrating lymphocytes (TILs) in biopsies of human HER2+ BC. Using a single cell resolution spatial transcriptomic Xenium instrument we find not only expression of CXCR3 by TILs, but can also track the distance and gradients of the chemokine ligands CXCL9 and CXCL10 in this tumor microenvironment. Having confirmed the activity of this axis in human HER2+ BC, we used our well-established spontaneous HER2-driven mouse model to compare treatment of HER2+ tumors with pIL-12-EP or pCXCL9-EP intratumorally. We observed tumor growth inhibition in both treatment groups as compared to control treated tumors. Interestingly, the abscopal effect previously seen with pIL-12-EP was not evident for distant tumors in mice treated with pCXCL9-EP. These data suggest that IT CXCL9 therapies may benefit from combination with a systemic immune activator like a vaccine or immunogenic chemotherapy. Ongoing studies will continue to evaluate ways to better target this axis therapeutically and define clinically active combination therapies. Citation Format: Anchit Bhagat, Jesuchristopher Joseph, Joshua D. Ginzel, Christopher Rabiola, Amy C. Hobeika, Joshua C. Snyder, Herbert K. Lyerly, Erika J. Crosby. Targeting the CXCR3 axis in HER2+ breast cancer to enhance anti-tumor immunity [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 2458.

Intratumoral delivery of a highly active form of XCL1 enhances antitumor CTL responses through recruitment of CXCL9‐expressing conventional type‐1 dendritic cells

Therapeutic Effect of MIP-1alpha-recruited Dendritic Cells on Preestablished Solid and Metastatic Tumors.

Efficacy of Intrathecal Delivery of Peptide-Pulsed Type 1 Conventional Dendritic Cell Vaccine for the Treatment of Breast Cancer-Associated Leptomeningeal Disease in Preclinical Models.

Gel-mediated recruitment of conventional type 1 dendritic cells potentiates the therapeutic effects of radiotherapy

Specific Inhibition Of Tumor Growth By T Cell Receptor-Drug Conjugates Targeting Intracellular Cancer-Testis Antigen Ny-Eso-1/Lage-1

Intratumoral Delivery of CCL25 Enhances Immunotherapy Against Triple-Negative Breast Cancer by Recruiting CCR9+ T Cells

The XCL1-Mediated DNA Vaccine Targeting Type 1 Conventional Dendritic Cells Combined with Gemcitabine and Anti-PD1 Antibody Induces Potent Antitumor Immunity in a Mouse Lung Cancer Model

CX3CR1+CD8+ T cells: Key players in antitumor immunity

XCL1/Glypican-3 Fusion Gene Immunization Generates Potent Antitumor Cellular Immunity and Enhances Anti-PD-1 Efficacy

Targeted Delivery of CXCL9 and OX40L by Mesenchymal Stem Cells Elicits Potent Antitumor Immunity.

Dendritic Cell-Targeting Chemokines Inhibit Colorectal Cancer Progression

CXCR6 is required for antitumor efficacy of intratumoral CD8 + T cell

Abstract 6349: Targeting the CXCR3 pathway with a novel peptide drug candidate mobilizes the immune system to enhance anti-tumor immunity

Cationic Liposome/DNA Complexes Mediate Antitumor Immunotherapy by Promoting Immunogenic Tumor Cell Death and Dendritic Cell Activation

Abstract 2458: Targeting the CXCR3 axis in HER2+ breast cancer to enhance anti-tumor immunity

Integrating individual functional moieties of CXCL10 and CXCL11 into a novel chimeric chemokine leads to synergistic antitumor effects: a strategy for chemokine-based multi-target-directed cancer therapy

Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade

Abstract 4208: In situ vaccination of non-small cell lung cancer with CXCL9/10-engineered dendritic cells combined with PD-1 blockade

Combinational delivery of TLR4 and TLR7/8 agonist enhanced the therapeutic efficacy of immune checkpoint inhibitors to colon tumor

Abstract 7633: CXCR6 positive circulating mucosal-associated invariant T cells play the anti-tumor effect in non-small cell lung caner immunotherapy

Therapeutically targeting type I interferon directly to XCR1+ dendritic cells reveals the role of cDC1s in anti-drug antibodies